Compare AXR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | GNLX |
|---|---|---|
| Founded | 1961 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 132.7M |
| IPO Year | 2010 | 2022 |
| Metric | AXR | GNLX |
|---|---|---|
| Price | $25.21 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $17.25 |
| AVG Volume (30 Days) | 11.7K | ★ 135.6K |
| Earning Date | 03-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | 9.47 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $12,831,000.00 | $8,000.00 |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $2.29 |
| 52 Week High | $29.01 | $8.54 |
| Indicator | AXR | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 45.57 |
| Support Level | $24.25 | $2.33 |
| Resistance Level | $28.84 | $2.97 |
| Average True Range (ATR) | 0.75 | 0.17 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 5.25 | 35.42 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.